SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Procter & Gamble Health Ltd

BSE: 500126 NSE: PGHL ISIN: INE199A01012
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Procter & Gamble Health Ltd belong to?
Procter & Gamble Health Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Procter & Gamble Health Ltd a good quality company?
Procter & Gamble Health Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Procter & Gamble Health Ltd undervalued or overvalued?
Procter & Gamble Health Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Procter & Gamble Health Ltd a good buy now?
Procter & Gamble Health Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd revenue growth is 8.2% for FY-2025 , which is above its 5 year CAGR of 4.3% , indicating faster growth.
Q.2 Gross Profit margin of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Gross profit margin which is the profit after deduction of direct costs, is 31.9% for FY-2025 , which is above its 5 year median of 25.8% , indicating increasing margins.
Q.3 Operating Profit Margin of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 34.11% for FY-2025 , which is above its 5 year median of 26.62% indicating increasing margins.
Q.4 Net Profit Margin of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Net Profit Margin is 25.09% for FY-2025 , is above with its 5 year median of 17.53%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 31.9 25.8
Operating Profit Margin 34.11 26.62
Net Profit Margin 25.09 17.53
Q.5 Return on Asset of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Return on Asset is 30.85%, which is above its 5 year historical median of 11%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Return on equity is 44.15% for FY-2025 , which is above its historical median of 31.58%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Return on capital employed is 58.05% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Cash conversion cycle is -36 days, below its historical median of -33 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.35 0.64
ROE 44.15 31.58
ROCE 58.05 42.52
Cash Conversion Cycle -36 days -33 days
Q.9 Debt to Equity ratio of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Procter & Gamble Health Ltd?
Promoters hold 51.82% of the Procter & Gamble Health Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Procter & Gamble Health Ltd vs industry peers?
Procter & Gamble Health Ltd revenue CAGR is 4.31% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,245.6 137.1
Gross Profit 298 15.1
Operating Profit 318 16
Net Profit 234 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.35 0.8
ROE 44.15 8.91
ROCE 58.05 11.59
Cash Conversion Cycle (days) -35.74 76

Valuation & price assessment

Q.1 Stock return of Procter & Gamble Health Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 22.7% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 22.7% -4.6% 2% -4%
Q.3 Valuation ratios of Procter & Gamble Health Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 28.24 50.51 40.28
Price to Book 11.88 9.19 2.77
Price to Sales 6.15 9.33 2.65
EV to EBITDA 19.12 31.37 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×